PURPOSE: Although few studies have explored age-related health care disparities, some researchers have asserted such disparities uniformly disfavor the elderly and are largely attributable to ageism in the health care system. We compared age-related patterns of screening for colorectal cancer with those for breast and prostate cancer in persons aged 50 years and older. METHODS: We analyzed data for all adults aged 50 years and older (N = 88,213) in the 2001 Behavioral Risk Factor Surveillance System (BRFSS), a nationally representative, telephone-administered survey of personal health behaviors. Main outcome measures were adjusted prevalence by 5-year age-groups of colorectal cancer screening using fecal occult blood testing, flexible sigmoidoscopy, or colonoscopy for men and women; rates of mammography screening for women; and rates of prostate-specific antigen (PSA) screening for men. RESULTS: After adjustment for race/ethnicity, education level, income, health insurance, and self-rated health, predicted reported colorectal cancer screening (all modalities) increased significantly from when patients reached age 50 years until 70 to 74 years (66.0%, standard error [SE] 0.8%), remained constant until age 80 years, and then declined. The age-related gain in colorectal cancer screening was confined to whites among patients older than 60 years. Reported PSA screening increased until age 75 to 79 years (79.3%, SE 1.1%) and then declined, whereas reported mammography screening peaked at age 55 to 59 years (83.3%, SE 1.2%) and then declined. CONCLUSIONS: Significant age-related disparities appear to exist for both evidence-based and non-evidence-based cancer-screening interventions. The issue of age-related disparities in cancer screening is complex, with the direction of disparity favoring the elderly for some services yet disfavoring them for others.
PURPOSE: Although few studies have explored age-related health care disparities, some researchers have asserted such disparities uniformly disfavor the elderly and are largely attributable to ageism in the health care system. We compared age-related patterns of screening for colorectal cancer with those for breast and prostate cancer in persons aged 50 years and older. METHODS: We analyzed data for all adults aged 50 years and older (N = 88,213) in the 2001 Behavioral Risk Factor Surveillance System (BRFSS), a nationally representative, telephone-administered survey of personal health behaviors. Main outcome measures were adjusted prevalence by 5-year age-groups of colorectal cancer screening using fecal occult blood testing, flexible sigmoidoscopy, or colonoscopy for men and women; rates of mammography screening for women; and rates of prostate-specific antigen (PSA) screening for men. RESULTS: After adjustment for race/ethnicity, education level, income, health insurance, and self-rated health, predicted reported colorectal cancer screening (all modalities) increased significantly from when patients reached age 50 years until 70 to 74 years (66.0%, standard error [SE] 0.8%), remained constant until age 80 years, and then declined. The age-related gain in colorectal cancer screening was confined to whites among patients older than 60 years. Reported PSA screening increased until age 75 to 79 years (79.3%, SE 1.1%) and then declined, whereas reported mammography screening peaked at age 55 to 59 years (83.3%, SE 1.2%) and then declined. CONCLUSIONS: Significant age-related disparities appear to exist for both evidence-based and non-evidence-based cancer-screening interventions. The issue of age-related disparities in cancer screening is complex, with the direction of disparity favoring the elderly for some services yet disfavoring them for others.
Authors: Jerry H Gurwitz; Robert J Goldberg; Judith A Malmgren; Hal V Barron; Alan J Tiefenbrunn; Paul D F Frederick; Joel M Gore Journal: Am J Med Date: 2002-05 Impact factor: 4.965
Authors: Michael S Simon; Sylvia Wassertheil-Smoller; Cynthia A Thomson; Roberta M Ray; F Allan Hubbell; Lawrence Lessin; Dorothy S Lane; Lew H Kuller Journal: Breast Cancer Res Treat Date: 2014-09-25 Impact factor: 4.872
Authors: C Daniel Mullins; Lisa Blatt; Confidence M Gbarayor; Hui-Wen Keri Yang; Claudia Baquet Journal: Am J Health Syst Pharm Date: 2005-09-15 Impact factor: 2.637
Authors: Samuel N Forjuoh; Charles Huber; Jane N Bolin; Shivajirao P Patil; Manisha Gupta; Janet W Helduser; Sonia Holleman; Marcia G Ory Journal: Patient Educ Couns Date: 2010-09-21
Authors: Nga T Nguyen; Elaine J Savoy; Lorraine R Reitzel; Minh-Anh H Nguyen; David W Wetter; Jacqueline Reese-Smith; Lorna H McNeill Journal: Health Behav Policy Rev Date: 2017-03
Authors: Constantine Daskalakis; Melissa DiCarlo; Sarah Hegarty; Anuragh Gudur; Sally W Vernon; Ronald E Myers Journal: Prev Med Date: 2020-02-08 Impact factor: 4.018